Lipid lowering and coronary heart disease risk: How appropriate are the national guidelines?

Medical Journal of Australia

Volumn 175, Issue 9, 2001, Pages 471-475

  Forge, B H ^a   Briganti, E M ^a  

^a Obstetrics West Gippsland Hospital   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL;

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DRUG FORMULARY; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PRIMARY PREVENTION; RISK FACTOR;

EID: 0035813340     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2001.tb143679.x     Document Type: Article

References (23)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
4. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
5. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
6. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
7. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
8. An updated coronary risk profile. A statement for health professionals
9. Joint British recommendations on prevention of coronary heart disease in clinical practice
10. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
11. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia
12. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating acute coronary risk in high risk men
13. Using the Framingham model to predict heart disease in the United Kingdom: Retrospective study
14. Prediction of coronary heart disease mortality in Busselton, Western Australia: An evaluation of the Framingham, national health epidemiologic follow up study, and WHO ERICA risk scores
15. Joint British recommendations on prevention of coronary heart disease in clinical practice: Summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, and British Diabetic Association
16. Carcinogenicity of lipid-lowering drugs
17. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project